



PHARMA MONTHLY

AUGUST 2021

PROGRESSIVE[®]
Your Progress Our Priority...

Equities | Derivatives | Commodities | Currency | Depository | Mutual Funds | NBFC | e-Broking



Key News for the Month

Company

- Bharat Biotech's Rotavac 5D receives WHO Prequalification
- Glenmark inks deal with SaNOTize for Covid treatment spray in India, other Asian markets
- Alkem Laboratories launches Ibuprofen, Famotidine tablets in US market
- Aurobindo Pharma channelising efforts to commercialise Covid-19 vaccine
- Alembic Pharma gets final approval from USFDA for OCD treatment drug
- Johnson & Johnson seeks emergency use nod for Covid vaccine in India
- Strides Pharma Science to acquire Endo's manufacturing facility in US along with basket of ANDAs
- RDIF proposes Pfizer conduct joint trials with Sputnik Light as booster shot
- Unichem Labs receives ANDA approval for Metformin Hydrochloride ER tablets
- Covid-19: Wockhardt inks pact with RDIF to produce, supply Sputnik vaccine
- Bharat Biotech gets nod for Phase 2/3 trials of intranasal Covid vaccine
- Lupin receives tentative USFDA approval for Brivaracetam Tablets
- Aurobindo Pharma's Rs420cr deal to acquire 51% in Cronus Pharma cancelled
- Cadila inks pact with Italian firm to launch generic product in US
- Johnson & Johnson seeks nod for trial of single-dose vaccine on adolescents in India
- Natco Pharma loses patent litigation case over anti-cancer drug Ibrutinib in the US
- Aurobindo, Cadila, UPL in fray to acquire bankrupt Sterling Biotech
- Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity
- Zydus Cadila expects to meet 50 million Covid vaccine target by January
- Cipla, Kemwell Biopharma join hands to develop biosimilars
- Bharat Biotech, IVI launch Chikungunya Vaccine Phase 2/3 trial in Costa Rica
- Zydus Cadila's Covid-19 vaccine can be available from first week of October
- SII informs Centre it will supply around 20 crore Covishield doses in September
- Wockhardt, Jemincare partner for novel respiratory antibiotic Nafithromycin
- Marksans Pharma receives USFDA approval for Acetaminophen ER Tablets, 650 mg (OTC)

Industry

- Pharma industry reports 75 deals worth USD26.6bn in July 2021: GlobalData
- Pharma APIs, once a sleepy sector, is the flavour of the season
- India will likely restart exporting Covid-19 vaccines in 2022: Government Official
- Indian pharma exporters stare at Afghan uncertainty; USD126mn target in FY22 on blink

Global

- Bayer buys Vividion Therapeutics for up to USD2bn
- Sierra Oncology licenses myelofibrosis candidate from AstraZeneca
- Pfizer and BioNTech announce submission of initial data to USFDA to support booster dose of Covid-19 vaccine
- SK bioscience and GSK start Phase 3 trial of adjuvanted Covid-19 vaccine candidate

Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Alembic	Clomipramine Hydrochloride Capsules	25/50/75mg	Indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD)	Anafranil Capsules (SpecGX LLC)	USD32mn
Unichem	Metformin Hydrochloride ER Tablets	500/750mg	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	Glucophage XR Tablets (EMD Serono Inc.)	USD254.5mn (2020-Global sales)
Lupin	Brivaracetam Tablets	10/25/50/75/100 mg	Indicated for the treatment of partial-onset seizures in patients four years of age and older	Briviact Tablets (UCB Inc.)	USD311mn (Annual sales)
Cadila	Tofacitinib ER Tablets	11/22mg	Indicated for the treatment of adult patients with active psoriatic arthritis	XELJANZ XR (Pfizer Inc.)	USD2082mn (Annual sales)
Marksans	Acetaminophen ER Tablets	650mg (OTC)	Used to treat mild to moderate pain (from headaches, menstrual periods) and to reduce fever	Tylenol ER Tablets (Johnson & Johnson Consumer Inc.)	-
Aurobindo	Cyclophosphamide Injection	500mg/2.5mL and 1g/5mL vials	Used to treat cancer	-	USD170mn
Aurobindo	Droxidopa Capsules	100/200/300mg	Used to treat dizziness and lightheadedness	Northera Capsules (Lundbeck NA)	USD352mn
Granules	Acetaminophen ER Tablets	650mg (OTC)	Indicated for the treatment of arthritis pain	Tylenol ER Tablets (Johnson & Johnson Consumer Inc.)	-

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	616	-8.1%	-2.5%	-77.3%
Abbott India Ltd	19260	-2.5%	32.9%	17.6%
Ajanta Pharma Ltd	2229	-1.4%	26.8%	50.2%
Albert David Ltd	579	5.7%	43.1%	35.9%
Alembic Ltd	105	-14.7%	3.0%	22.4%
Alembic Pharmaceuticals Ltd	751	-3.9%	-18.7%	-20.1%
Alkem Laboratories Ltd	3879	11.4%	37.7%	42.6%
Apollo Hospitals Enterprise Ltd	4969	22.7%	61.3%	204.2%
Aster DM Healthcare Ltd	214	31.8%	49.1%	64.2%
AstraZeneca Pharma India	3107	-7.6%	-10.1%	-12.6%
Aurobindo Pharma Ltd	727	-20.8%	-16.7%	-10.1%
Biocon Ltd	359	-8.1%	-9.3%	-4.7%
Bliss GVS Pharma Ltd	112	-12.0%	-36.1%	-22.3%
Cadila Healthcare Ltd	554	-6.4%	27.2%	49.2%
Caplin Point Laboratories Ltd	730	-18.5%	56.2%	42.9%
Cipla Ltd	947	2.8%	20.0%	33.0%
Dishman Carbogen Amics Ltd	186	-11.2%	57.1%	5.4%
Divi's Laboratories Ltd	5172	4.9%	49.4%	66.3%
Dr. Reddy's Laboratories Ltd	4702	0.01%	5.6%	10.4%
Dr. Lal PathLabs Ltd	4058	9.2%	73.8%	128.5%
Eris Lifesciences Ltd	732	-4.7%	23.0%	51.8%
FDC Ltd	346	-6.8%	24.1%	11.1%
Fermenta Biotech Ltd	287	-8.4%	1.7%	-17.3%
Fortis Healthcare Ltd	291	15.6%	70.3%	119.2%
Gland Pharma Ltd	3891	-1.0%	64.9%	-
GSK Pharmaceuticals Ltd	1531	-4.6%	5.3%	-2.2%
Glenmark Pharmaceuticals Ltd	530	-12.5%	13.4%	13.0%
Granules India Ltd	331	-13.6%	-3.0%	5.7%
Gufic Biosciences Ltd	185	-4.3%	55.4%	124.0%
HealthCare Global Enterprises Ltd	240	-6.7%	43.0%	97.9%
Hester Biosciences Ltd	2402	-0.7%	38.6%	69.5%
Hikal Ltd	632	15.2%	295.2%	288.6%
Indoco Remedies Ltd	480	1.4%	61.3%	109.4%
Indraprastha Medical Corp. Ltd	77	-7.4%	43.4%	53.3%
IOL Chemicals and Pharma Ltd	559	-16.8%	1.9%	-26.1%


Source: BSE website; All prices are as on 31st Aug 2021

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
IPCA Laboratories Ltd	2582	22.7%	35.7%	37.5%
J.B.Chemicals & Pharma Ltd.	1702	-5.3%	48.4%	121.1%
Laurus Labs Ltd	666.6	1.9%	83.4%	-41.0%
Lincoln Pharmaceuticals Ltd	331	-8.3%	41.0%	50.5%
Lupin Ltd	958	-14.8%	-6.3%	3.3%
Marksans Pharma Ltd	71	-13.9%	26.3%	55.2%
Max Healthcare Institute Ltd	386	30.7%	107.4%	260.5%
Metropolis Healthcare Ltd	2821	-2.3%	44.5%	50.9%
Morepen Laboratories Ltd	53	-18.6%	80.8%	89.2%
Narayana Hrudayalaya Ltd	541	8.8%	24.4%	67.5%
Natco Pharma Ltd	944	-6.5%	15.2%	25.4%
Neuland Laboratories Ltd	1633	-17.3%	-20.5%	82.6%
Novartis India Ltd	771	-20.7%	25.4%	24.1%
Panacea Biotec Ltd	299	-4.8%	52.8%	60.0%
Pfizer Ltd (India)	5720	-3.2%	23.5%	24.5%
Poly Medicare Ltd	955	-1.4%	32.2%	137.9%
Procter & Gamble Health Ltd	5435	-0.1%	-17.7%	13.2%
RPG Life Sciences Ltd	498	-2.8%	19.4%	49.5%
Sanofi India Ltd	9020	5.6%	9.2%	9.3%
Sequent Scientific Ltd	230	-20.5%	-7.1%	77.1%
Shalby Ltd	196	-2.4%	83.9%	138.5%
Shilpa Medicare Ltd	577	-10.6%	57.0%	9.7%
Solara Active Pharma Sciences Ltd	1623	-6.3%	22.7%	74.0%
Strides Pharma Science Ltd	614	-19.5%	-26.5%	1.7%
SPARC Ltd	300	7.0%	80.9%	66.6%
Sun Pharmaceutical Industries Ltd	794	2.5%	31.4%	53.2%
Suven Life Sciences Ltd	83	0.1%	-1.7%	67.8%
Suven Pharmaceuticals Ltd	536	3.4%	12.5%	-15.6%
Syngene International Ltd	642	1.2%	15.2%	35.5%
Take Solutions Ltd	52	-17.4%	-8.3%	2.8%
Thyrocare Technologies Ltd	1299	-1.4%	41.1%	73.1%
Torrent Pharmaceuticals Ltd	3104	0.9%	27.3%	16.7%
Unichem Laboratories Ltd	293	-6.6%	-9.0%	21.9%
Vimta Labs Ltd	297	-6.4%	79.8%	183.5%
Wockhardt Ltd	405	-23.3%	-18.9%	29.7%

Source: BSE website; All prices are as on 31st Aug 2021

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1 M	6 M	12 M
Aurobindo Pharma Ltd.	727	426212	-20.76%	-16.7%	-10.1%
Biocon Ltd.	359	430320	-8.1%	-9.3%	-4.7%
Cadila Healthcare Ltd.	554	566744	-6.4%	27.2%	49.2%
Cipla Ltd.	947	764008	2.8%	20.0%	33.0%
Divi's Laboratories Ltd.	5172	1372950	4.9%	49.4%	66.3%
Dr. Reddy's Laboratories Ltd.	4702	782300	0.01%	5.6%	10.4%
Alkem Laboratories Ltd.	3879	463745	11.4%	37.7%	42.6%
Lupin Ltd.	958	434725	-14.8%	-6.34%	3.3%
Torrent Pharmaceuticals Ltd.	3104	525335	0.9%	27.30%	16.7%
Sun Pharmaceutical Industries Ltd.	794	1905432	2.5%	31.4%	53.2%

Source: NSE website, Company Research; All prices are as on 31st Aug 2021



Source: NSE website

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Mr. Shyam Agrawal,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.